Adicet Bio, Inc. (ACET) Stock Analysis — March 2026 Rating, Price, and Forecast
Company Overview — What Does Adicet Bio, Inc. Do?
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts. Adicet Bio, Inc. (ACET) is classified as a micro-cap stock in the Manufacturing sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Chen Schor and employs approximately 90 people. With a market capitalization of $0, ACET is one of the notable companies in the Manufacturing sector.
Adicet Bio, Inc. (ACET) Stock Rating — Strong Buy (March 2026)
As of March 2026, Adicet Bio, Inc. receives a Strong Buy rating with a composite score of 86.8/100 and 5 out of 5 stars from the Blank Capital Research quantitative model.ACET ranks #652 out of 7,333 stocks in our coverage universe. Within the Manufacturing sector, Adicet Bio, Inc. ranks #272 of 1931 stocks, placing it in the top quartile of its Manufacturing peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
ACET Stock Price and 52-Week Range
Adicet Bio, Inc. (ACET) currently trades at $6.99. The stock lost $0.30 (4.2%) in the most recent trading session. Recent trading volume was 83K shares, suggesting relatively thin trading activity.
Is ACET Overvalued or Undervalued? — Valuation Analysis
Adicet Bio, Inc. (ACET) carries a value factor score of 50/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The price-to-book ratio stands at 0.64x, versus the sector average of 2.40x.
Overall, ACET's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
Adicet Bio, Inc. Profitability — ROE, Margins, and Quality Score
Adicet Bio, Inc. (ACET) earns a quality factor score of 25/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -107.0%, compared to the Manufacturing sector average of -5.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -83.1% versus the sector average of -1.9%.
Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
ACET Debt, Balance Sheet, and Financial Health
Adicet Bio, Inc. has a debt-to-equity ratio of 29.0%, compared to the Manufacturing sector average of 20.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.00x, indicating strong short-term liquidity.
ACET has a beta of 0.03, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Adicet Bio, Inc. is 35/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
Adicet Bio, Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Adicet Bio, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.29. Net income for the quarter was $-117M. Operating income came in at $-123M.
In Q3 2025, Adicet Bio, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.29. Net income for the quarter was $-27M. Operating income came in at $-28M.
In Q2 2025, Adicet Bio, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.34. Net income for the quarter was $-31M. Operating income came in at $-32M.
In Q1 2025, Adicet Bio, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.31. Net income for the quarter was $-28M. Operating income came in at $-30M.
Over the past 8 quarters, Adicet Bio, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing ACET stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
ACET Dividend Yield and Income Analysis
Adicet Bio, Inc. (ACET) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Manufacturing dividend stocks may want to explore other Manufacturing stocks or use the stock screener to filter by dividend yield.
ACET Momentum and Technical Analysis Profile
Adicet Bio, Inc. (ACET) has a momentum factor score of 99/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 58/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 45/100 reflects moderate short selling activity.
ACET vs Competitors — Manufacturing Sector Ranking and Peer Comparison
Within the Manufacturing sector, Adicet Bio, Inc. (ACET) ranks #272 out of 1931 stocks based on the Blank Capital composite score. This places ACET in the top quartile of all Manufacturing stocks in our coverage universe. Key competitors and sector peers include INTERPARFUMS INC (IPAR) with a score of 94.5/100, BK Technologies Corp (BKTI) with a score of 91.7/100, Fitell Corp (FTEL) with a score of 90.7/100, Park Ha Biological Technology Co., Ltd. (BYAH) with a score of 85.0/100, and TENAX THERAPEUTICS, INC. (TENX) with a score of 82.9/100.
Comparing ACET against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ACET vs S&P 500 (SPY) comparison to assess how Adicet Bio, Inc. stacks up against the broader market across all factor dimensions.
ACET Next Earnings Date
No upcoming earnings date has been announced for Adicet Bio, Inc. (ACET) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy ACET? — Investment Thesis Summary
The bull case for Adicet Bio, Inc. rests on several quantitative strengths. The quality score of 25/100 flags below-average profitability. Price momentum is positive at 99/100, suggesting the trend favors buyers. High volatility (stability score 35/100) increases portfolio risk.
In summary, Adicet Bio, Inc. (ACET) earns a Strong Buy rating with a composite score of 86.8/100 as of March 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ACET stock.
Related Resources for ACET Investors
Explore more research and tools: ACET vs S&P 500 comparison, top Manufacturing stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ACET head-to-head with peers: ACET vs IPAR, ACET vs BKTI, ACET vs FTEL.